Login
SANUWAVE Health, Inc. logo

SANUWAVE Health, Inc.

sanuwave.com

What Do They Do?

Sells ultrasound wound-treatment systems and single-use applicators to hospitals, clinics, and other wound-care providers.

How Do They Make Money?

Customers buy systems, consumables, parts, and accessories when goods ship. The company also earns extended-warranty and rental revenue over their terms, license fees under agreement terms, and repair revenue when work is performed.

revenue
SegmentShareRevenue
Consumables, parts, and accessories revenue
Sold outright

59%
System revenue
Sold outright

41%
FY2022: 34%
Extended warranty
Recurring
0.4%
License fees
Licensed
0.1%
Other
Mix
0.5%

Who Are Their Customers?

Hospitals, clinics, and other care facilities, as well as mobile wound-care providers, use its systems; sales go through Sanuwave's direct representatives, independent distributors, and resellers.

Do Revenues Turn Into Profits?

Yes. It kept 27 cents of every revenue dollar as net income in FY2025 and turned 4 cents into free cash flow.

Operating income, FY2025
11% of revenue
▲ +29% vs FY2024 ($3.8M, 12%)
Net income, FY2025
27% of revenue
▲ Turned profitable vs FY2024 (−$33.1M, −101%)
Free cash flow, FY2025
4% of revenue
▼ −2% vs FY2024 ($2M, 6%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −24%
vs $11.3M in Q3 FY2025
Net income
▼ Turned to a loss
vs $9.7M in Q3 FY2025
  • Sep 23, 2026 Nasdaq notified Sanuwave of a listing-rule deficiency Its listing continues during a 180-day compliance period; failure to regain the required market value could lead to delisting.
  • Jun 16, 2026 Sanuwave lowered its second-quarter revenue guidance It cited market disruption affecting sales of new UltraMIST systems.

Growing. Revenue grew 3.4x in 4 years, from $13M in FY2021 to $44.1M in FY2025, about 36% a year.

PACE product line exited The older report named both UltraMIST and PACE as systems for continued commercialization; the latest report says PACE was sold and disposed of and identifies UltraMIST as its only commercial product.

Revenue over time
Consumables, parts, and accessories revenue System revenue Extended warranty License fees Other License Fees and Other Consumables and Parts Revenue
$50M$25M$0

Who Do They Compete With?

Competes with Solventum, Smith & Nephew, Molnlycke Health Care, Essity, Coloplast, Convatec, Organogenesis, MiMedx Group, Integra LifeSciences, Vericel, Kerecis, Arobella Medical, NanoVibronix, SoftWave Tissue Regeneration Technologies, MolecuLight, and MIMOSA Diagnostics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support